Literature DB >> 26324294

Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.

Sebastiano Leone1, Silvana Noviello2, Silvano Esposito3.   

Abstract

INTRODUCTION: Enterococci are common causes of infective endocarditis (IE) in both health care and community-based setting. Enterococcal IE requires bactericidal therapy for an optimal outcome. For decades, cell-wall-active antimicrobial agents (penicillins or vancomycin) in combination with aminoglycosides were the cornerstone of the treatment; however, the emergence of antibiotic resistance has significantly reduced the efficacy of these regimens.
MATERIALS AND METHODS: Data for this review were identified by searches of MEDLINE and references from relevant articles on antibiotic combination regimens for the treatment of enterococcal IE. Abstracts presented in scientific conferences were not searched for.
CONCLUSION: New effective and safe combination treatments, including double-β-lactam and daptomycin/β-lactam combination, are proving useful for the management of IE due to enterococci.

Entities:  

Keywords:  Combination antibiotic therapy; Enterococcus spp.; Infective endocarditis

Mesh:

Substances:

Year:  2015        PMID: 26324294     DOI: 10.1007/s15010-015-0836-0

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  85 in total

1.  In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model.

Authors:  L B Rice; C T Eliopoulos; J D Yao; G M Eliopoulos; R C Moellering
Journal:  Diagn Microbiol Infect Dis       Date:  1992-02       Impact factor: 2.803

2.  Gentamicin once-daily in enterococcal endocarditis.

Authors:  Matteo Bassetti; Elda Righi; Massimo Crapis; Piergiorgio Cojutti; Sergio Venturini; Pierluigi Viale; Federico Pea
Journal:  Int J Cardiol       Date:  2013-07-30       Impact factor: 4.164

3.  Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis.

Authors:  Jolanta Piszczek; James Hutchinson; Eric Partlow
Journal:  J Antimicrob Chemother       Date:  2014-09-22       Impact factor: 5.790

4.  Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used?

Authors:  Lars Olaison; Kimmo Schadewitz
Journal:  Clin Infect Dis       Date:  2001-12-07       Impact factor: 9.079

5.  Epidemiology, characteristics, and outcome of infective endocarditis in Italy: the Italian Study on Endocarditis.

Authors:  S Leone; V Ravasio; E Durante-Mangoni; M Crapis; G Carosi; P G Scotton; N Barzaghi; M Falcone; P Chinello; M B Pasticci; P Grossi; R Utili; P Viale; M Rizzi; F Suter
Journal:  Infection       Date:  2012-06-19       Impact factor: 3.553

6.  Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.

Authors:  A Lefort; A Saleh-Mghir; L Garry; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

7.  β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.

Authors:  Jordan R Smith; Katie E Barber; Animesh Raut; Mostafa Aboutaleb; George Sakoulas; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2015-02-01       Impact factor: 5.790

8.  Failure of linezolid treatment for enterococcal endocarditis.

Authors:  S M Zimmer; A M Caliendo; M C Thigpen; J Somani
Journal:  Clin Infect Dis       Date:  2003-07-16       Impact factor: 9.079

Review 9.  Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic.

Authors:  Marianne Billeter; Marcus J Zervos; Anne Y Chen; Joseph R Dalovisio; Changa Kurukularatne
Journal:  Clin Infect Dis       Date:  2008-02-15       Impact factor: 9.079

10.  High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis.

Authors:  Manuela Carugati; Arnold S Bayer; Josè M Miró; Lawrence P Park; Armenio C Guimarães; Athanasios Skoutelis; Claudio Q Fortes; Emanuele Durante-Mangoni; Margaret M Hannan; Francisco Nacinovich; Nuria Fernández-Hidalgo; Paolo Grossi; Ru-San Tan; Thomas Holland; Vance G Fowler; Ralph G Corey; Vivian H Chu
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

View more
  5 in total

Review 1.  Resistance Mechanisms, Epidemiology, and Approaches to Screening for Vancomycin-Resistant Enterococcus in the Health Care Setting.

Authors:  Matthew L Faron; Nathan A Ledeboer; Blake W Buchan
Journal:  J Clin Microbiol       Date:  2016-05-04       Impact factor: 5.948

2.  A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone.

Authors:  Ivone Jimenez-Toro; Carlos A Rodriguez; Andres F Zuluaga; Julian D Otalvaro; Omar Vesga
Journal:  PLoS One       Date:  2020-12-08       Impact factor: 3.240

3.  Synergistic Combination of Linezolid and Fosfomycin Closing Each Other's Mutant Selection Window to Prevent Enterococcal Resistance.

Authors:  Lifang Jiang; Na Xie; Mingtao Chen; Yanyan Liu; Shuaishuai Wang; Jun Mao; Jiabin Li; Xiaohui Huang
Journal:  Front Microbiol       Date:  2021-02-09       Impact factor: 5.640

4.  A retrospective clinical comparison of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections.

Authors:  Yu-Chung Chuang; Pao-Yu Chen; Chi-Ying Lin; Yee-Chun Chen; Jann-Tay Wang; Shan-Chwen Chang
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

Review 5.  Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis.

Authors:  Marco Fiore; Alberto Enrico Maraolo; Ivan Gentile; Guglielmo Borgia; Sebastiano Leone; Pasquale Sansone; Maria Beatrice Passavanti; Caterina Aurilio; Maria Caterina Pace
Journal:  World J Hepatol       Date:  2017-10-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.